CHRISTOPHER BURNS: Open Payments
NPI 1841396017 · LONGVIEW, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,346 in 79 payments from 17 companies in 2025. Trend: 2023 $9,581 · 2024 $6,207 · 2025 $1,346
Food & beverage: $1,346
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 31 | $446 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 12 | $167 |
| Ipsen Biopharmaceuticals, Inc | 2 | $161 |
| Janssen Biotech, Inc. | 10 | $161 |
| Phathom Pharmaceuticals, Inc. | 5 | $62 |
| Lilly USA, LLC | 4 | $58 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $54 |
| Madrigal Pharmaceuticals | 2 | $38 |
| Novo Nordisk Inc | 2 | $38 |
| Ferring Pharmaceuticals Inc. | 1 | $29 |
Products named: RINVOQ, IQIRVO, TREMFYA, SKYRIZI, RELISTOR, CREON, XIFAXAN, VOQUEZNA.
Industry payments across TX — which companies pay providers there.
